Viking Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92686J1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of J Matthew Singleton. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate J Matthew Singleton has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:VKTX / Viking Therapeutics, Inc. Director 9,500
US:CBST / Director 1,104
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by J Matthew Singleton. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases VKTX / Viking Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in VKTX / Viking Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-05-31 VKTX SINGLETON J MATTHEW 9,500 9.8169 9,500 9.8169 93,261 111 19.65 93,415 100.17

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VKTX / Viking Therapeutics, Inc. Insider Trades
Insider Sales VKTX / Viking Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in VKTX / Viking Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VKTX / Viking Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by J Matthew Singleton as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-10-25 2024-10-25 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -16,000 9,500 -62.75 79.50 -1,272,000 755,250
2024-10-25 2024-10-25 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
M - Exercise X 16,000 25,500 168.42 4.48 71,680 114,240
2024-09-20 2024-09-20 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -10,300 9,500 -52.02 69.50 -715,850 660,250
2024-09-20 2024-09-20 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
M - Exercise X 10,300 19,800 108.42 1.19 12,257 23,562
2024-08-22 2024-08-21 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -5,700 9,500 -37.50 69.72 -397,430 662,384
2024-08-22 2024-08-21 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
M - Exercise X 5,700 15,200 60.00 1.19 6,783 18,088
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -1,501 9,500 -13.64 64.88 -97,385 616,358
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -2,388 11,001 -17.84 64.10 -153,080 705,205
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -2,055 13,389 -13.31 63.15 -129,775 845,527
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -4,509 15,444 -22.60 61.86 -278,931 955,381
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -3,047 19,953 -13.25 61.13 -186,248 1,219,629
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -2,500 23,000 -9.80 60.01 -150,034 1,380,317
2024-08-19 2024-08-19 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
M - Exercise X 16,000 25,500 168.42 3.33 53,280 84,915
2024-08-14 2024-08-14 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -160 9,500 -1.66 58.37 -9,339 554,504
2024-08-14 2024-08-14 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
S - Sale X -20,626 9,660 -68.10 57.52 -1,186,397 555,638
2024-08-14 2024-08-14 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
M - Exercise X 20,786 30,286 218.80 8.00 166,288 242,288
2022-01-05 2022-01-03 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2021-01-06 2021-01-04 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2020-01-03 2020-01-02 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2019-01-03 2019-01-02 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2018-05-31 2018-05-31 4 VKTX Viking Therapeutics, Inc.
Common Stock, par value $0.00001 per share
P - Purchase 9,500 9,500 9.82 93,261 93,261
2018-01-03 2018-01-02 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,000 16,000
2017-01-05 2017-01-03 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,000 16,000
2016-01-06 2016-01-04 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16,000 16,000
2015-04-30 2015-04-28 4 VKTX Viking Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,786 20,786
2013-06-14 2013-06-12 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
A - Award 1,104 1,104
2013-06-14 2013-06-12 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 8,370 8,370
2013-06-11 2013-06-06 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -1,347 0 -100.00
2013-06-11 2013-06-06 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 1,347 4,972 37.16
2013-05-22 2013-05-22 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -17,500 0 -100.00
2013-05-22 2013-05-22 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -10,000 0 -100.00
2013-05-22 2013-05-22 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -27,500 3,625 -88.35 55.48 -1,525,755 201,122
2013-05-22 2013-05-22 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 17,500 31,125 128.44 22.71 397,425 706,849
2013-05-22 2013-05-22 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 10,000 13,625 275.86 9.56 95,600 130,255
2012-08-27 2012-08-24 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -2,500 0 -100.00
2012-08-27 2012-08-24 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -2,500 3,625 -40.82 45.52 -113,800 165,010
2012-08-27 2012-08-24 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 2,500 6,125 68.97 10.09 25,225 61,801
2012-06-11 2012-06-06 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
A - Award 1,347 1,347
2012-06-11 2012-06-06 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 9,367 9,367
2012-03-12 2012-03-09 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -10,000 2,500 -80.00
2012-03-12 2012-03-09 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -10,000 3,625 -73.39 43.06 -430,565 156,080
2012-03-12 2012-03-09 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 10,000 13,625 275.86
2012-02-06 2012-02-03 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -2,000 0 -100.00
2012-02-06 2012-02-03 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -2,000 3,625 -35.56 42.28 -84,562 153,269
2012-02-06 2012-02-03 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 2,000 5,625 55.17 11.89 23,780 66,881
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)